Oramed Pharmaceuticals Inc. (ORMP) Stock Price

ORMPStock

$4.07+79.30%52W

Market Cap$166.57M

P/E2.64x

PEG Ratio—

Div yield0.00%

Beta1.28

ORMP Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-2.80%

Price vs S&P 500 (4W)-12.08%

VGM Score57.79

P/E Ratio (Annual)2.64x

Indicated Dividend Yield (Annual)0.00%

Book Value / Share (Quarterly)$7.68

P/TBV (Annual)0.58x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-9.52%

Cash Flow / Share (Quarterly)$-0.13

Price vs S&P 500 (YTD)30.88%

Gross Margin (TTM)0.65%

Net Profit Margin (TTM)-838.40%

EPS (TTM)$4.13

10-Day Avg Trading Volume0.14M

EPS Excl Extra (TTM)$4.13

Revenue Growth (5Y)-5.83%

EPS (Annual)$1.51

ROI (Annual)32.07%

Gross Margin (Annual)0.65%

Net Profit Margin (5Y Avg)29.27%

Cash / Share (Quarterly)$1.23

P/E Basic Excl Extra (TTM)0.97x

Revenue Growth QoQ (YoY)-100.00%

P/E Normalized (Annual)2.64x

ROA (Last FY)27.74%

Revenue Growth TTM (YoY)-30.93%

EBITD / Share (TTM)$-0.34

ROE (5Y Avg)-1.74%

Operating Margin (TTM)-1070.36%

Cash Flow / Share (Annual)$-0.23

P/B Ratio0.53x

P/B Ratio (Quarterly)0.62x

Net Income / Employee (Annual)$4,926,900

EV / Revenue (TTM)58.67x

Net Interest Coverage (TTM)-2.84x

ROA (TTM)64.18%

EPS Growth QoQ (YoY)508.30%

EV / EBITDA (TTM)1.25x

EPS Incl Extra (Annual)$1.51

Current Ratio (Annual)6.98x

Quick Ratio (Quarterly)4.77x

3-Month Avg Trading Volume0.26M

52-Week Price Return79.30%

P/E Incl Extra (TTM)0.97x

Revenue / Employee (TTM)$118,882,400,000

Tangible BV / Share (Quarterly)$3.70

P/S Ratio (Annual)126.34x

Asset Turnover (Annual)0.01x

52-Week High$5.47

Operating Margin (5Y Avg)-1139.09%

EPS Excl Extra (Annual)$1.51

CapEx CAGR (5Y)-52.70%

26-Week Price Return7.11%

Quick Ratio (Annual)6.84x

13-Week Price Return0.99%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.98x

Enterprise Value$154.06M

Revenue / Share Growth (5Y)-13.06%

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)9.17%

Revenue / Employee (Annual)$103,100

Pretax Margin (Annual)379.70%

Cash / Share (Annual)$3.21

3-Month Return Std Dev41.60%

Gross Margin (5Y Avg)78.65%

Net Income / Employee (TTM)$13,451,500

ROE (Last FY)32.07%

Net Interest Coverage (Annual)-0.46x

EPS Basic Excl Extra (Annual)$1.51

P/FCF (TTM)78.66x

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$4.13

ROI (TTM)72.96%

P/S Ratio (TTM)43.31x

Pretax Margin (5Y Avg)108.79%

Revenue / Share (Annual)$0.03

Tangible BV / Share (Annual)$3.84

Forward P/E0.91x

Price vs S&P 500 (52W)63.76%

P/E Ratio (TTM)0.97x

EPS Growth TTM (YoY)60.34%

Year-to-Date Return42.81%

5-Day Price Return-4.68%

EPS Normalized (Annual)$1.51

ROA (5Y Avg)-2.24%

Net Profit Margin (Annual)412.31%

Month-to-Date Return-12.85%

Cash Flow / Share (TTM)$-0.42

EBITD / Share (Annual)$-0.35

Operating Margin (Annual)-1176.79%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-1.90%

P/E Excl Extra (TTM)0.97x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$4.13

P/TBV (Quarterly)0.59x

P/B Ratio (Annual)0.57x

Pretax Margin (TTM)-838.40%

Book Value / Share (Annual)$5.09

Price vs S&P 500 (13W)-1.69%

Beta1.28x

P/FCF (Annual)35.12x

Revenue / Share (TTM)$0.05

ROE (TTM)72.96%

52-Week Low$2.09

vGradeC

gGradeC

mGradeB

vgmGradeC

ORMP Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 10, 2026	$0.43	$1.84	+327.91%(+$1.41)
Q1 2026	May 19, 2026	—	$0.91	—
Q4 2025	Mar 26, 2026	$0.00	$0.25	+0.00%(+$0.25)
Q3 2025	Nov 13, 2025	-$0.04	$1.13	+2925.00%(+$1.17)
Q2 2025	Aug 14, 2025	-$0.04	$0.31	+875.00%(+$0.35)

ORMP Analyst Recommendations

Mar 2025

Apr 2025

May 2025

Jun 2025

2.17

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ORMPOramed Pharmaceuticals Inc.	C	C	B	43.3x	-30.9%	0.7%	—	$4.07
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals develops proprietary oral delivery technology for therapeutic proteins, including insulin, designed to survive the stomach's harsh environment. The platform enables injectable biologics to be administered as oral medications, potentially improving patient convenience and compliance. Its clinical pipeline includes ORMD-0801 for diabetes and ORMD-0901.